Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, November 16th. The stock was sold at an average price of $100.96, for a total value of $706,720.00. Following the completion of the transaction, the insider directly owned 31,771 shares in the company, valued at $3,207,600.16. This trade represents a 18.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Joana Goncalves also recently made the following trade(s):
- On Thursday, October 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $74.81, for a total value of $523,670.00.
- On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86.
Oruka Therapeutics Stock Performance
Shares of NASDAQ ORKA traded down $6.11 during mid-day trading on Monday, hitting $99.24. The stock had a trading volume of 989,987 shares, compared to its average volume of 1,082,544. Oruka Therapeutics, Inc. has a 1 year low of $25.23 and a 1 year high of $115.51. The business has a 50 day moving average price of $89.68 and a two-hundred day moving average price of $72.36. The firm has a market cap of $6.73 billion, a P/E ratio of -47.03 and a beta of -0.34.
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). Equities research analysts predict that Oruka Therapeutics, Inc. will post -2.52 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on the company. Wall Street Zen cut Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Guggenheim reaffirmed a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a research report on Monday, October 26th. BTIG Research reiterated a “buy” rating and issued a $151.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, November 10th. Finally, Wedbush reiterated an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, October 27th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $141.80.
Get Our Latest Stock Analysis on Oruka Therapeutics
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Oruka Therapeutics during the second quarter valued at $474,916,000. Remedium Capital Partners LLC boosted its holdings in shares of Oruka Therapeutics by 0.9% during the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after buying an additional 13,247 shares in the last quarter. Jupiter Topco LLC bought a new stake in shares of Oruka Therapeutics during the 2nd quarter valued at $130,968,000. Avidity Partners Management LP grew its position in shares of Oruka Therapeutics by 15.1% in the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock worth $37,299,000 after buying an additional 100,000 shares during the period. Finally, Voya Investment Management LLC grew its position in shares of Oruka Therapeutics by 2.9% in the 3rd quarter. Voya Investment Management LLC now owns 412,814 shares of the company’s stock worth $34,383,000 after buying an additional 11,665 shares during the period. 56.44% of the stock is currently owned by institutional investors.
Oruka Therapeutics Company Profile
Oruka Therapeutics is a clinical-stage biotechnology company developing long-acting antibody medicines for chronic inflammatory skin diseases. Its research focuses on pathways involved in conditions such as plaque psoriasis, with the goal of extending the time between treatments. The company’s pipeline includes ORKA-001, an antibody targeting interleukin-23 (IL-23), and ORKA-002, which targets interleukin-17A and interleukin-17F (IL-17A/F). Both programs are being developed as potential treatments for inflammatory skin conditions.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
